Aligos Therapeutics Inc
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly mo… Read more
Aligos Therapeutics Inc (ALGS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.339x
Based on the latest financial reports, Aligos Therapeutics Inc (ALGS) has a cash flow conversion efficiency ratio of -0.339x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-24.34 Million) by net assets ($71.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aligos Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Aligos Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Aligos Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aligos Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cavatina Holding S.A.
WAR:CAV
|
0.003x |
|
Perintis Triniti Properti PT
JK:TRIN
|
0.006x |
|
Research Frontiers Incorporated
NASDAQ:REFR
|
-0.096x |
|
374Water Inc. Common Stock
NASDAQ:SCWO
|
-0.398x |
|
ACC Binh Duong Investment and Construction JSC
VN:ACC
|
N/A |
|
Samkee Automotive Co. Ltd
KQ:122350
|
0.043x |
|
TIAN GE INT.HLDGS DL-0001
F:04T
|
N/A |
|
TransAct Technologies Incorporated
NASDAQ:TACT
|
0.114x |
Annual Cash Flow Conversion Efficiency for Aligos Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Aligos Therapeutics Inc from 2018 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $53.55 Million | $-82.50 Million | -1.541x | -155.29% |
| 2024-12-31 | $-28.97 Million | $-80.74 Million | 2.787x | +424.84% |
| 2023-12-31 | $92.08 Million | $-79.00 Million | -0.858x | -12.28% |
| 2022-12-31 | $103.90 Million | $-79.39 Million | -0.764x | -22.04% |
| 2021-12-31 | $184.73 Million | $-115.66 Million | -0.626x | -85.51% |
| 2020-12-31 | $220.04 Million | $-74.26 Million | -0.337x | -146.83% |
| 2019-12-31 | $-64.89 Million | $-46.77 Million | 0.721x | +63.80% |
| 2018-12-31 | $-13.75 Million | $-6.05 Million | 0.440x | -- |